In the case of DY635-functionalized PLGA nanoparticles, it would be beneficial to package Cas9 mRNA with sgRNAs, that complementary targets the individual BCR-ABL1 breakpoint of CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.